FindTrial
Sign In

Efficacy of Ayush medicine NOQ19 in treatment of Covid-19 patients

A randomized, double blind, placebo controlled, multi-centric, trial to determine the therapeutic efficacy of Ayush medicine NOQ19 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033790
Enrollment
150
Registered
2021-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ayurveda Medicine NOQ 19: 500 mg , 2tabs thrice daily orally with water in morning, Noon and Night. Duration of therapy: 7 days Control Intervention1: Placebo: 500 mg , 2tabs thrice d

Sponsors

Sriveda Sattva Private Limited Sri Sri Tattva
Lead Sponsor
Sri Sri Institute for Advanced Research SSIAR
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Symptomatic COVID 19 infection with or without comorbidities Willingness to participate in the study Indian nationals

Exclusion criteria

Exclusion criteria: Age less than 18 years or more than 75 years Pregnancy and Lactation Patient not willing to participate in the study

Design outcomes

Primary

MeasureTime frame
To evaluate the effect of NOQ19 in COVID 19 patients in time to become SARS COV2 RT-PCR negative, reducing the symptoms and duration of hospital stayTimepoint: 7 days for each participant—

Secondary

MeasureTime frame
Effect of NOQ19 therapy on laboratory parameters - CBC, RBS, KFT, LFT, CRPTimepoint: Entry and Exit—

Countries

India

Contacts

Public ContactDr Naveen K H

AIIMS

pankajbhardwajdr@gmail.com8003996903

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 9, 2026